Lilly Names New Business Leaders

INDIANAPOLIS, Sept. 14 /PRNewswire-FirstCall/ -- In conjunction with today's
announcement of a new operating model to speed innovative medicines to
patients, Eli Lilly and Company (NYSE: LLY) has named the leaders of its
Development Center of Excellence and its five business units: oncology,
diabetes, established markets, emerging markets, and Elanco animal health.
These leaders will provide improved line of sight to Lilly's customers. Each
will carry clear decision-making authority and accountability for their
respective parts of the business.

The new leaders are:

Tim Garnett, M.D., and Tom Verhoeven, Ph.D., will lead the Development Center
of Excellence within Lilly Research Laboratories. Garnett will have
responsibility for medical, regulatory, global product safety, translational
medicine and global health outcomes. Verhoeven will have responsibility for
the clinical development organization, product R&D, toxicology/ADME and
project management.

John H. Johnson will lead the oncology business unit. Johnson currently serves
as chief executive officer of ImClone Systems, a wholly-owned subsidiary of
Lilly.

Enrique A. Conterno will lead the diabetes business unit. Conterno currently
serves as president of Lilly USA, the company's U.S. business operations.

Bryce D. Carmine will lead the established markets business unit. Carmine
currently serves as Lilly's executive vice president of global marketing and
sales.

Jacques Tapiero will lead the emerging markets business unit. Tapiero
currently serves as Lilly's president of the intercontinental region.

Jeffrey N. Simmons will lead Elanco, the animal health business unit, where he
currently serves as president.

Appointments for each of the four pharmaceutical business unit leaders and the
two leaders of the Development Center of Excellence will become effective on
November 1, 2009.

"These are proven leaders who bring a wealth of experience and knowledge to
their respective roles," said John C. Lechleiter, Ph.D., Lilly chairman,
president and chief executive officer. "Each has demonstrated strong
leadership and an ability to get results throughout their business careers.
Moving forward, these individuals will play a critical role in the success of
Lilly's new operating model."

Lechleiter also outlined the details of the Development Center of Excellence,
while explaining the criteria used to establish Lilly's new business units:

-- Development Center of Excellence - With over 60 molecules in clinical
development, the Development Center of Excellence (COE) will be tasked
with streamlining the development of pipeline molecules and speeding
innovative medicines to patients. The ultimate goal of the Development
COE is to accelerate the launch of important Lilly molecules over the
next decade and bring innovative medicines to patients sooner.

-- Oncology - With the acquisition of ImClone and the progression of its
own pipeline, Lilly remains intent on building an oncology powerhouse.
Currently, one-third of the company's pipeline is composed of
molecules to treat various forms of cancer. The need for new and
better
treatments is staggering: the World Health Organization estimates 12
million cancer-related deaths per year by 2030.

-- Diabetes - Lilly has long been a leader in diabetes care, with a
dedicated asset base and a portfolio of commercially successful
products
and promising pipeline opportunities. The need for new and improved
treatments for patients with diabetes is great: an estimated 246
million
adults are affected worldwide. In addition, Lilly remains one of only
a
few global insulin suppliers.

-- Established Markets - Lilly's other important therapeutic areas,
including neuroscience, osteoporosis/bone and cardiovascular, are
included in the established markets business unit. The established
markets business unit will have geographic responsibility for these
therapeutic areas in the United States, Japan, the European Union,
Canada, and Australia / New Zealand. This business unit will also host
Lilly's global marketing organization.

-- Emerging Markets - The emerging markets business unit will include
many
of the world's fastest-growing markets, such as China, Russia,
Brazil, Mexico, South Korea and Turkey. Lilly aims to increase its
presence in these countries and others where strong growth rates for
pharmaceuticals are projected over the next decade. The creation of an
emerging markets business unit will increase the company's focus on
these areas and best position Lilly to serve growing patient needs
among
two-thirds of the world's population.

-- Elanco Animal Health - Lilly remains committed to its animal health
business. Elanco sales continue to grow at a rate faster than the
overall animal health market. Elanco is positioned to deliver
double-digit earnings growth over the next five years, bolstered by
several recent acquisitions and the launch of its companion animal
business.

Additional details about the new leaders of Lilly's Development Center of
Excellence and five business units:

Dr. Tim Garnett is currently chief medical officer and senior vice president
of global medical, regulatory and safety for Lilly. During his 11-year tenure
at Lilly, Garnett has served as vice president for global patient safety;
global brand development leader; as group medical director responsible for the
development of duloxetine; and European clinical research physician for
raloxifene.

Prior to joining Lilly, Garnett acquired seven years of experience, holding a
variety of positions in the pharmaceutical industry in Europe with Organon
Laboratories.

Garnett qualified in medicine at St. George's Hospital in London. He practiced
obstetrics and gynecology for eight years prior to joining the pharmaceutical
industry and conducted clinical research into menopause, premenstrual tension
and postmenopausal osteoporosis. He is a fellow of the Royal College of
Obstetricians and Gynecologists in the United Kingdom and a fellow of the
Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He is a
member of the Royal Society of Medicine.

Thomas Verhoeven, Ph.D., joined Lilly as vice president for product research
and development in June 2003 responsible for the chemical, bioproduct,
analytical, pharmaceutical and devices operations. In 2008, he was promoted to
senior vice president of global product development. His current
responsibilities include management of the therapeutic area platform teams
including neuroscience, diabetes and endocrine, osteoporosis, oncology, and
CV/acute care. He also directs global clinical operations and health outcomes.
This responsibility includes all of the Phase III development work required
for presubmission of new products and the ongoing development work required to
support life cycle plans for those products already marketed. Verhoeven is a
member of the LRL policy committee, the portfolio management committee and the
corporate operations committee. He is also chair of the product development
committee.

Prior to joining Lilly, Verhoeven worked for Merck Research Laboratories for
23 years. Within Merck Research Laboratories, he was responsible for the
process development and commercialization of multiple products across a range
of therapeutic classes, global operations and strategic research planning.

Verhoeven received a bachelor of science degree in chemistry from the
University of Michigan, a doctorate in organic chemistry from the University
of Wisconsin, and an appointment as a National Institutes of Health (NIH)
fellow at Stanford University.

John H. Johnson has served as chief executive officer of ImClone Systems since
August 2007. He also served as a member of the company's board of directors
until the company was acquired by Lilly in November 2008.

Prior to joining ImClone, Johnson served as company group chairman of Johnson
& Johnson's Worldwide Biopharmaceuticals unit. In this executive role, he was
responsible for the Johnson & Johnson Biotechnology, Immunology and Oncology
commercial businesses, including Centocor, Inc., Ortho Biotech Products, L.P.
and the Worldwide Strategic Marketing group. Earlier in his career, Johnson
held roles of increasing responsibility in sales and sales management at
Pfizer before joining Johnson & Johnson to help lead their entry into the
anti-infectives business. He advanced through positions of increasing
responsibility with Ortho-McNeil, including leading the commercial groups
responsible for the development of sales, marketing and new product strategies
of several of the company's flagship brands.

Johnson received a bachelor of science degree from East Stroudsburg University
of Pennsylvania. He is also a member of the boards of BioNJ and Cempra
Pharmaceuticals.

Enrique A. Conterno was promoted to president of Lilly USA in January 2009. He
is a member of Lilly's operations committee and senior management council.
Prior to his promotion, Conterno served as senior vice president of health
care professional markets for Lilly USA.

Born in Lima, Peru, Conterno earned a master of business administration degree
at Duke University in 1992. He earned his bachelor's degree in mechanical
engineering from Case Western Reserve University in 1989.

Conterno joined Lilly as a sales representative in 1992. From 1993 to 1995, he
held roles as a financial analyst, marketing associate, and business
development manager. In 1996, Conterno became sales and marketing director for
the Peru affiliate, and in 1998, he became the sales and marketing director
for Lilly's affiliate in Brazil. In 2000, Conterno was named executive
director of marketing for the intercontinental region and Japan. Conterno
served as president and general manager for Lilly's operations in Mexico in
2003, and was named vice president of Lilly USA's neuroscience business unit
in July 2006. He serves on the Board of Visitors of the Fuqua School of
Business at Duke University.

Bryce D. Carmine was named executive vice president, global marketing and
sales, in April 2008. Prior to this position, Carmine had been president,
global product development, with responsibility for the development of the
late-phase pipeline molecules at Lilly. Prior to assuming this position,
Carmine had a series of leadership roles that related to overseeing late-phase
development of molecules for multiple therapeutic areas. His current
responsibilities include leadership of the global pharmaceutical marketing and
sales organizations across Lilly. He is a member of the company's executive
committee and operations committee.

Born in New Zealand, Carmine received a bachelor of science in biochemistry
from Massey University in 1973. He joined Lilly in 1975 in New Zealand and
subsequently held several marketing and management positions in New Zealand
before moving in 1983 to the company's corporate headquarters in Indianapolis.

In 1986, he was named general manager of Daewoong-Lilly Pharmaceutical Company
in South Korea, a joint venture between Lilly and Daewoong. He became managing
director of Lilly operations in Australia in 1989. During his tenure in
Australia, he was actively involved in the Australian Pharmaceutical Research
and Manufacturers Association, holding the position of chairman from 1992 to
1995. Carmine then served as the president and general manager of Lilly Japan
from 1995 to June 1999 before returning to Indianapolis.

Jacques Tapiero was named president of the intercontinental region for Lilly
in November 2004. The intercontinental region comprises offices in Asia,
Australia, Africa and Middle East countries, Canada, Latin America and Russia.
He also is a member of the company's senior management council. Tapiero had
been president and general manager of Lilly France since December 1999.

Born in Morocco, Tapiero is a Swiss citizen who in 1980 received a master of
business administration degree from the Ecole Superieure de Commerce at
Clermond Ferrand in France. In 1982, he obtained a second master of business
administration degree at the American Graduate School of International
Management in Glendale, Arizona.

Tapiero joined Lilly in 1983 as a financial analyst. He held several sales and
finance positions in Indianapolis, France and Switzerland. He was named
managing director of Lilly Sweden in 1993. From 1995 to 1999, Tapiero was
president and general manager at Lilly Brazil. In late 1999, Tapiero was named
president and general manager for Lilly France.
Tapiero is a member of the Thunderbird Global Council, a council of leading
business executives who advise Thunderbird, the School of Global Management.

Jeff N. Simmons was named president of Elanco, the animal health division of
Lilly, in January 2008.

Simmons received a bachelor's degree in agricultural economics and marketing
from Cornell University in 1989. Simmons joined Lilly in 1989 in sales. He has
held numerous positions over the last 19 years within Elanco, including
executive director of global strategy, operations and research and
development; area director, Western Europe, based in the United Kingdom; and
country director for Brazil, located in Sao Paulo. He has managed Elanco's
international marketing for cattle and poultry and has also held other
marketing and sales management positions in Elanco's domestic and
international areas.

Simmons is a leading spokesperson on the role of technology in the global food
chain, as well as change leadership and execution in the agricultural and food
industries. He is a member of the Animal Health Institute's executive
committee and is chairman of its board of directors. He is also a member of
Harvard's PAPSAC committee (Private and Public, Scientific, Academic, and
Consumer Food Policy Council) and is chairman of the FFA Sponsors Board.

About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing
portfolio of pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent scientific
organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -
through medicines and information - for some of the world's most urgent
medical needs. Additional information about Lilly is available at
www.lilly.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

C-LLY

SOURCE Eli Lilly and Company

Edward G. Sagebiel, +1-317-433-9899, egs@lilly.com (Media), or Mark E. Taylor,
+1-317-276-5795; mark.taylor@lilly.com (Media), or Philip Johnson,
+1-317-655-6874; johnson_philip_l@lilly.com (Investors)